Literature DB >> 8452660

Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

A G Johnson1, P Seideman, R O Day.   

Abstract

The prevalence and incidence of adverse drug interactions involving nonsteroidal anti-inflammatory drugs (NSAIDs) remains unknown. To identify those proposed drug interactions of greatest clinical significance, it is appropriate to focus on interactions between commonly used and/or commonly coprescribed drugs, interactions for which there are numerous well documented case reports in reputable journals, interactions validated by well designed in vivo human studies and those affecting high-risk drugs and/or high-risk patients. While most interactions between NSAIDs and other drugs are pharmacokinetic, NSAID-related pharmacodynamic interactions may be considerably more important in the clinical context, and prescriber ignorance is likely to be a major determinant of many adverse drug interactions. Prescribing NSAIDs is relatively contraindicated for patients on oral anticoagulants due to the risk of haemorrhage, and for patients taking high-dose methotrexate due to the dangers of bone marrow toxicity, renal failure and hepatic dysfunction. Combination NSAID therapy cannot be justified as toxicity may be increased without any improvement in efficacy. Where lithium or anti-hypertensives are coprescribed with NSAIDs, close monitoring is mandatory for lithium toxicity and hypertension, respectively, and aspirin (acetylsalicylic acid) or sulindac are preferred. Phenytoin or oral hypoglycaemic agents may be administered with NSAIDs other than pyrazoles and salicylates provided that patients are monitored carefully at the initiation and cessation of NSAID treatment. Digoxin, aminoglycosides and probenecid may be coprescribed with NSAIDs, but close monitoring is required, particularly for high-risk patients such as the elderly. Indomethacin and triamterene should be avoided due to the risk of renal failure. High dose aspirin should be replaced by naproxen in patients on valproic acid (sodium valproate) and care is required when corticosteroids are administered to patients taking salicylates long term in high dosage. Interactions between NSAIDs and antacids or cholestyramine are generally avoidable. Adverse drug interactions involving NSAIDs may be limited by rational prescribing and by careful monitoring, particularly for high-risk patients, drugs and therapy periods.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452660     DOI: 10.2165/00002018-199308020-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  222 in total

Review 1.  Drug use in the elderly: a review of problems and special considerations.

Authors:  R E Vestal
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

2.  Antagonistic effect of non-steroidal anti-inflammatory drugs on frusemide-induced diuresis in cardiac failure.

Authors:  A C Laiwah; R A Mactier
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-12

3.  A double-blind crossover study to compare the efficacy of three dosage levels of flurbiprofen in the treatment of rheumatoid disease and osteoarthrosis.

Authors:  N Cardoe
Journal:  Curr Med Res Opin       Date:  1977       Impact factor: 2.580

4.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

5.  Effect of antacid and ascorbic acid on serum salicylate concentration.

Authors:  P D Hansten; W L Hayton
Journal:  J Clin Pharmacol       Date:  1980 May-Jun       Impact factor: 3.126

6.  The effects of discontinuing long-term diuretic therapy in the elderly.

Authors:  M L Burr; S King; H E Davies; M S Pathy
Journal:  Age Ageing       Date:  1977-02       Impact factor: 10.668

7.  Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.

Authors:  G Ciabattoni; G A Cinotti; A Pierucci; B M Simonetti; M Manzi; F Pugliese; P Barsotti; G Pecci; F Taggi; C Patrono
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

8.  Additive effect of combined naproxen and paracetamol in rheumatoid arthritis.

Authors:  P Seideman
Journal:  Br J Rheumatol       Date:  1993-12

9.  Flurbiprofen interaction with single doses of atenolol and propranolol.

Authors:  J Webster; J C Petrie; I McLean; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

10.  The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study.

Authors:  N Baber; L Halliday; R Sibeon; T Littler; M L Orme
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

View more
  9 in total

1.  Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy.

Authors:  Maria Chiara Silvani; Domenico Motola; Elisabetta Poluzzi; Ambrogio Bottoni; Fabrizio De Ponti; Alberto Vaccheri; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2006-01-17       Impact factor: 2.953

Review 2.  NSAIDs and blood pressure. Clinical importance for older patients.

Authors:  A G Johnson
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 3.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

Review 4.  Analgesic abuse in the elderly. Renal sequelae and management.

Authors:  M M Elseviers; M E De Broe
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

Review 5.  NSAIDs and increased blood pressure. What is the clinical significance?

Authors:  A G Johnson
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

Review 6.  Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role.

Authors:  Maryam Al Hussaini; Emad I Hammouda; Ahmed E Hammouda
Journal:  Int J Clin Pharm       Date:  2014-07-02

Review 7.  Risks and benefits of drugs used in the management and prevention of gout.

Authors:  P G Conaghan; R O Day
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

Review 8.  Physiological aspects of aging. Implications for the treatment of cancer.

Authors:  S M Lichtman
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

9.  Pain management in people with severe mental illness: an agenda for progress.

Authors:  Juliana Onwumere; Brendon Stubbs; Mary Stirling; David Shiers; Fiona Gaughran; Andrew S C Rice; Amanda C de C Williams; Whitney Scott
Journal:  Pain       Date:  2022-03-16       Impact factor: 7.926

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.